With this uterine implant, will the HIV pandemic soon become a past?

This is good news only for the weaker sex: Canadian and Kenyan scientists have successfully developed a kind of uterine implant that helps effectively prevent it.

The test, published in this Journal of Controlled Release, shows that the device can successfully activate the 'Immune inactivity' state on rabbit experimental models, through slow release of the memory. hydroxychloroquine immunity.

If a human clinical trial demonstrates three factors: effective, inexpensive and safe, this will be the key to preventing the outbreak of this century's disease, especially in populated areas. expensive as Africa.

The HIV virus can only replicate in the human body after it sticks to the surface of T lymphocyte immune cells. Normally, when any type of organism enters the body, these immune cells are will quickly appear and kill pathogens, but with HIV, the virus will cling to immune cells, shelter there and wait for the opportunity to multiply.

Uterine implant device for HIV prevention.

The suppression of immediate immune response from the border guard will first eliminate the opportunity for 'nesting' HIV in our bodies.

The idea of ​​this device comes from previous research by two scientists Emmanuel Ho and Keith Fowke. They found that a group of research subjects that had a 'immune inactivation' status seemed to be immune to HIV.

'When we see this, we find that we can trigger immunity of immunity through drugs, and even so, we can control this immunity in this condition. levels to avoid further infecting other bacteria. This is not a bad idea, because by attaching the drug to this device, we can cause targeted immunity, thereby making the process faster, safer and more effective. ' - the two researchers said.

Hydroxychloroquine is a drug that has been around for a long time, and they were first used to make anti-malarial drugs.

Later, the drug was used in many different autoimmune diseases, after it was discovered its immunosuppressive role. It is also the drug used in this study thanks to a strong inhibitor on T-cell lymphocytes, the primary residence of the HIV virus.

According to the research team, there is still a need for a number of larger-scale studies conducted on humans, to confirm the effectiveness and safety of this device.

While waiting for its official presence in the market, we still have to be loyal to the traditional measures: safe sex and antiviral drugs for high-risk subjects. .